Johnson & Johnson Says Darzalex Regimens Show Meaningful Responses In Patients With Multiple Myeloma
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Johnson & Johnson (JNJ) Frday announced data from three studies highlighting clinical efficacy of Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) in maintenance regimens.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-139800984-5d6b247e19d94a4c86617ccf37b94a89.jpg "Are Credit Card Rewards Considered Taxable Income?")
:max_bytes(150000):strip_icc():format(jpeg)/INV_Gold_Bars_GettyImages-1852385549-f965387598f74025bc1eb57e9d49d05b.jpg "Got an Extra 0? Here’s How Much You Could Make in 20 Years Investing in Gold")
